Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Estimates By $0.68 EPS

Inovio Pharmaceuticals (NASDAQ:INO) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.31 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.37) by $0.68, FiscalAI reports.

Inovio Pharmaceuticals Stock Down 0.6%

INO stock traded down $0.01 during trading on Thursday, hitting $1.68. 748,919 shares of the company’s stock traded hands, compared to its average volume of 1,166,955. The stock has a market capitalization of $112.11 million, a price-to-earnings ratio of -0.65 and a beta of 1.70. Inovio Pharmaceuticals has a 52 week low of $1.30 and a 52 week high of $2.98. The stock has a fifty day moving average price of $1.65 and a two-hundred day moving average price of $2.06.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on INO shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Inovio Pharmaceuticals in a report on Monday, December 29th. HC Wainwright restated a “neutral” rating on shares of Inovio Pharmaceuticals in a research note on Tuesday, December 30th. UBS Group reiterated an “overweight” rating on shares of Inovio Pharmaceuticals in a research note on Friday, November 14th. Finally, Piper Sandler reissued an “overweight” rating and issued a $6.00 price objective (up from $5.00) on shares of Inovio Pharmaceuticals in a report on Friday, November 14th. Four equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $6.75.

Key Stories Impacting Inovio Pharmaceuticals

Here are the key news stories impacting Inovio Pharmaceuticals this week:

• Positive Sentiment: INO reported Q4 results and beat EPS expectations, reporting $0.31 vs. consensus (‐$0.37); management also provided FY commentary. This upside can support sentiment if revenue/cash guidance appears healthy. Quarterly Press Release
• Positive Sentiment: INOVIO announced its Biologics License Application (BLA) for INO-3107 has been accepted under FDA Accelerated Approval (PDUFA target Oct 30, 2026) and highlighted published immunologic/clinical data and new technology progress—news that materially de-risks and derivers potential near- to mid-term value drivers if approval/label is favorable. INOVIO Q4 & BLA Press Release
• Neutral Sentiment: Company science/tech publications and collaborations (Nature Communications, Nature Medicine, Dana-Farber collaboration, DMAb/DPROT preclinical data) signal scientific progress but will take time to translate into revenue; monitor clinical readouts and regulatory milestones. Scientific & Collaboration Details
• Negative Sentiment: Multiple securities-class-action developments: a class action has been filed (Pomerantz; Bronstein reports similar filings/claims alleging investor harm for purchases Oct 10, 2023–Dec 26, 2025), creating potential legal exposure, settlement risk and headline pressure. Pomerantz Filing
• Negative Sentiment: Several law firms (Rosen, Faruqi & Faruqi, Frank R. Cruz, Howard G., Bronstein) are soliciting lead plaintiffs ahead of an April 7, 2026 deadline—this flood of solicitations can amplify selling pressure and prolong volatility even if litigation outcomes are uncertain. Rosen Solicitation

Institutional Investors Weigh In On Inovio Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. Focus Partners Wealth bought a new position in Inovio Pharmaceuticals in the 3rd quarter worth approximately $33,000. Raymond James Financial Inc. raised its stake in Inovio Pharmaceuticals by 4,396.0% during the 3rd quarter. Raymond James Financial Inc. now owns 16,680 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 16,309 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new stake in Inovio Pharmaceuticals during the 3rd quarter valued at $41,000. Zacks Investment Management acquired a new position in Inovio Pharmaceuticals during the 3rd quarter worth $46,000. Finally, Caitong International Asset Management Co. Ltd boosted its position in Inovio Pharmaceuticals by 752.9% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 20,572 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 18,160 shares during the period. Institutional investors own 26.79% of the company’s stock.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.